Aortic Stenosis: Mechanisms and Management

Aortic stenosis represents one of the most prevalent and clinically consequential valvular heart diseases encountered in contemporary cardiovascular medicine. Characterized by progressive narrowing of the aortic valve orifice, this mechanical obstruction imposes substantial hemodynamic stress upon the left ventricle, fundamentally altering systemic circulatory dynamics and driving compensatory myocardial remodeling. Without timely diagnosis and targeted intervention, severe symptomatic disease carries a dismal prognosis, making an understanding of its pathophysiology, clinical trajectory, and therapeutic alternatives essential for clinicians and biomedical researchers alike.

Aortic Stenosis

1. Concise Definition

Aortic stenosis is a progressive valvular heart disease characterized by abnormal narrowing of the aortic valve orifice, which restricts blood flow from the left ventricle into the ascending aorta during ventricular systole. This pathological obstruction elevates transvalvular hemodynamic gradients, increases left ventricular afterload, and precipitates progressive compensatory concentric hypertrophy, diastolic dysfunction, and eventual heart failure.

In its typical clinical manifestation, aortic stenosis advances over several decades from subclinical leaflet thickening and sclerosis to profound anatomical calcification and severe functional outflow obstruction. When the effective orifice area diminishes sufficiently, patients develop the classic symptomatic triad of exertional angina, syncope, and dyspnea, heralding an abrupt escalation in the risk of sudden cardiac death in the absence of surgical or transcatheter intervention.

2. Etymology & Linguistic Origin

The term aortic stenosis derives from classical Greek and Latin anatomical roots. The word “aortic” originates from the ancient Greek aortē (α&#7f30;ορτή), used by Aristotle to describe the great artery of the heart, which in turn stems from the verb aeirein (α&#7f34;ρειν), meaning “to lift,” “to heave,” or “that which is suspended,” referring to the vessel’s anatomical suspension from the cardiac base. The noun “stenosis” is directly borrowed from the ancient Greek sten&omacron;sis (στένωσις), signifying a narrowing or constriction, derived from stenos (στενώς), meaning “narrow” or “strait.”

The compounding of these terms entered modern medical terminology during the early nineteenth century through French and British clinical pathomorphology. Pathologists such as Jean-Baptiste Bouillaud and early British clinicians systematically linked structural constrictions at the base of the left ventricle to systemic clinical signs, standardizing “aortic stenosis” within English medical nosology to indicate a discrete anatomical and hemodynamic entity.

3. Pronunciation & Grammatical Form

In standard English, the term is pronounced as follows: aortic is articulated as /eɪˈɔːrtɪk/ in American English and /eɪˈɔːtɪk/ in Received Pronunciation; stenosis is pronounced /stəˈnoʊsɪs/ (American) and /stəˈnəʊsɪs/ (British). Grammatically, the term functions as a compound noun phrase, with “aortic” acting as a classifying adjective modifying the non-count (or countable pathological) noun “stenosis.” The plural form is “aortic stenoses” (/stəˈnoʊsiːz/). Related derivative forms include the adjective “stenotic” (e.g., “a severely stenotic valve”) and the verb “stenose” (e.g., “the valvular apparatus progressively stenoses over time”).

4. Detailed Conceptual Explanation

Aortic stenosis represents an active, highly regulated biological process rather than a mere passive, “wear-and-tear” degenerative disease of aging. Historically conceptualized as an inevitable consequence of mechanical stress across the lifespan, contemporary molecular cardiology recognizes that the development of calcific aortic valve disease involves chronic endothelial disruption, subendothelial lipid accumulation, chronic inflammatory cell recruitment, extracellular matrix reorganization, and the differentiation of valvular interstitial cells into osteoblast-like phenotypes. This osteogenic transformation drives the active deposition of hydroxyapatite crystals within the fibrosa layer of the valve leaflets, resulting in marked structural stiffening, nodular thickening, and loss of leaflet excursion.

From a biomechanical and hemodynamic standpoint, normal adult aortic valve leaflets have an effective orifice area measuring between 3.0 and 4.0 cm². Because the aortic valve offers negligible resistance under physiological conditions, the systolic pressure difference between the left ventricle and the ascending aorta is minimal (<5 mmHg). However, as pathological processes reduce the valve area to less than 1.5 cm² (moderate stenosis) and ultimately to less than 1.0 cm² (severe stenosis), significant resistance to forward flow develops. To preserve forward cardiac output, the left ventricle must generate progressively higher peak systolic pressures, frequently surpassing 200 to 250 mmHg.

This sustained pressure overload stimulates a homeostatic molecular cascade within cardiac myocytes. In accordance with Laplace’s law—where wall stress is directly proportional to intracavitary pressure multiplied by radius and inversely proportional to wall thickness—the left ventricle responds by adding sarcomeres in parallel. This structural adaptation induces concentric left ventricular hypertrophy. While this compensatory hypertrophy initially normalizes systolic wall stress and preserves normal left ventricular ejection fraction, it simultaneously impairs ventricular relaxation and compliance. The stiffened myocardium demands higher end-diastolic filling pressures, relying heavily on vigorous left atrial contraction (“atrial kick”) to achieve adequate end-diastolic filling volume.

As the disease reaches its terminal decompensated stages, the limits of compensatory remodeling are breached. Progressive myocardial interstitial fibrosis, microvascular rarefaction, and mismatched coronary perfusion relative to muscle mass provoke subendocardial ischemia, even in the absence of epicardial coronary artery disease. Left ventricular systolic function ultimately declines, cardiac output drops, pulmonary capillary wedge pressure escalates, and frank congestive heart failure ensues.

5. Historical Development

The systematic description of aortic stenosis evolved in tandem with physical examination techniques and morbid anatomy in seventeenth- and eighteenth-century Europe. The pioneering French anatomist Théophile Bonet recorded early observations of ossified, narrowed heart valves in his landmark work Sepulchretum (1679). Giovanni Battista Morgagni subsequently provided detailed anatomical accounts in De Sedibus et Causis Morborum per Anatomen Indagatis (1761), establishing the direct causal link between structural rigidity of the aortic cusps and systemic circulatory failure.

The nineteenth century brought revolutionary advancements in bedside auscultation following René Laennec’s invention of the stethoscope in 1816. Clinicians could now reliably identify the characteristic harsh, crescendo-decrescendo systolic murmur radiating to the carotids. In the late nineteenth and early twentieth centuries, James Hope and later Sir William Osler codified the classical physical findings, including the delayed, weak arterial pulse (pulsus parvus et tardus). At this time, acute rheumatic fever was viewed as the predominant etiology underlying nearly all structural valvular disease.

The mid-twentieth century transformed aortic stenosis from an inevitably fatal diagnostic curiosity into an operable structural disorder. The introduction of invasive cardiac catheterization by André Cournand, Dickinson Richards, and Werner Forssmann allowed direct recording of transvalvular pressure gradients. In 1951, Richard Gorlin and Lewis Gorlin formulated the foundational Gorlin equation, mathematically deriving valve orifice area from cardiac output and the square root of the mean systolic pressure gradient. Open-heart surgical valve replacement became a clinical reality in the 1960s through the groundbreaking work of Albert Starr and Lowell Edwards, who successfully implanted mechanical ball-cage prostheses.

The late twentieth and early twenty-first centuries witnessed a paradigm shift toward non-invasive diagnostics via two-dimensional and Doppler echocardiography, largely replacing diagnostic cardiac catheterization. Furthermore, the advent of transcatheter aortic valve replacement (TAVR), pioneered by Alain Cribier in 2002, revolutionized modern therapeutics, allowing minimally invasive, catheter-based bioprosthetic valve deployment across high-, intermediate-, and low-risk patient populations.

6. Theoretical Foundations

The study and clinical management of aortic stenosis rest upon principles drawn from fluid mechanics, cellular biomechanics, and myocardial energetics. In hemodynamics, the law of conservation of mass, expressed through the continuity equation, provides the primary conceptual framework for calculating valve area non-invasively:

A₁ × V₁ = A₂ × V₂

Assuming fluid incompressibility, the stroke volume ejected through the left ventricular outflow tract (LVOT) must equal the stroke volume passing through the stenotic aortic valve orifice. By measuring the cross-sectional area and the velocity-time integral of the LVOT alongside the velocity-time integral across the aortic valve via Doppler ultrasound, clinicians calculate the effective valve area with high precision, overcoming flow-dependent variations in peak velocity.

Complementing macroscopic fluid dynamics, cellular and molecular paradigms illuminate the pathobiology of disease initiation and progression. Current cellular theories describe endothelial shear-stress injury along the aortic surface of the leaflets as the initiating trigger. This biomechanical trauma enables the entry and oxidation of low-density lipoproteins (LDL) and lipoprotein(a) [Lp(a)], igniting a cytokine-mediated inflammatory cascade involving interleukin-1β, tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta 1 (TGF-β1). In response, resident quiescent valvular interstitial cells transition into contractile myofibroblasts and subsequent osteoblast-like cells, transcribing runx2, osteopontin, and alkaline phosphatase, which directly orchestrates matrix calcification.

A third pillar is the theory of ventriculo-arterial coupling. This framework evaluates the heart and systemic vascular tree not as isolated components, but as an integrated mechanical unit. The left ventricle faces a double burden in aortic stenosis: the valvular load (valvular resistance) and the systemic vascular load (arterial compliance and systemic vascular resistance). The valvulo-arterial impedance index (Z_va) quantifies this total afterload, recognizing that elderly patients with aortic stenosis frequently suffer from concomitant systemic arterial stiffening, which exacerbates left ventricular mechanical fatigue and speeds symptomatic decompensation.

7. Key Components, Types & Dimensions

Aortic stenosis manifests across distinct anatomical variants, clinical stages, and hemodynamic subtypes:

• Etiological Variants:
  • Calcific Aortic Stenosis of Aging: The most common form in industrialized nations, typically presenting in individuals older than 65 years on anatomically normal tricuspid valves.
  • Congenital Bicuspid Aortic Valve (BAV): The most common congenital cardiac anomaly (present in 1–2% of the population); abnormal flow geometry increases mechanical stress, accelerating calcific degeneration by 10 to 20 years compared to tricuspid valves.
  • Rheumatic Aortic Stenosis: Results from recurrent rheumatic carditis; characterized by commissural fusion, leaflet thickening, and frequently concomitant mitral valve involvement.
• Hemodynamic Classifications (ACC/AHA Guidelines):
  • High-Gradient Severe Aortic Stenosis: Aortic valve area ≤1.0 cm² (or indexed area ≤0.6 cm²/m²), mean pressure gradient ≥40 mmHg, and peak jet velocity ≥4.0 m/s, associated with preserved left ventricular ejection fraction (≥50%).
  • Classical Low-Flow, Low-Gradient Aortic Stenosis: Valve area ≤1.0 cm², mean gradient <40 mmHg, reduced ejection fraction (<50%), and reduced stroke volume index (≤35 mL/m²). Requires dobutamine stress echocardiography to differentiate true-severe from pseudo-severe stenosis.
  • Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: Valve area ≤1.0 cm², mean gradient <40 mmHg, but with preserved ejection fraction (≥50%) and low stroke volume index (≤35 mL/m²), typically occurring in elderly females with severe concentric hypertrophy, small ventricular cavity size, and pronounced hypertension.
  • Normal-Flow, Low-Gradient Aortic Stenosis: Characterized by a valve area ≤1.0 cm² with a mean gradient <40 mmHg and a normal stroke volume index (>35 mL/m²); commonly reflects moderate stenosis with discordant measurement artifacts or systemic vascular compliance changes.

8. Examples & Illustrative Cases

To appreciate how aortic stenosis presents across clinical environments, consider two contrasting clinical profiles reflecting the major patient cohorts seen in practice:

Case 1: Congenital Bicuspid Valve Degeneration in a Middle-Aged Adult. A 54-year-old male marathon runner presents with progressive exertional chest tightness and lightheadedness during rigorous physical training over the preceding four months. He previously had no known medical conditions. On examination, a harsh 3/6 mid-systolic crescendo-decrescendo murmur is auscultated over the second right intercostal space, radiating prominently into both carotid arteries. Transthoracic echocardiography reveals a congenital bicuspid aortic valve (fusion of the right and left coronary cusps) with severe fibrocalcific degeneration, an effective valve area of 0.7 cm², a peak transvalvular velocity of 4.3 m/s, and a mean gradient of 48 mmHg. Left ventricular ejection fraction is preserved at 62%, but marked concentric hypertrophy is noted. Given his active lifestyle and severe symptoms, the patient is referred for surgical aortic valve replacement with a mechanical or bioprosthetic conduit following comprehensive shared decision-making.

Case 2: Paradoxical Low-Flow, Low-Gradient Stenosis in an Octogenarian. An 82-year-old female with long-standing essential hypertension presents to the clinic reporting debilitating fatigue, orthopnea, and lower extremity edema. Auscultation reveals a soft 2/6 systolic murmur and a diminished second heart sound (S₂). Initial echocardiography demonstrates a preserved ejection fraction of 55%, but an aortic valve area of 0.8 cm², a peak velocity of 3.2 m/s, and a mean gradient of only 31 mmHg. Because her stroke volume index is severely reduced at 28 mL/m² secondary to a diminutive, highly hypertrophied left ventricular cavity, non-contrast multidetector cardiac computed tomography is performed. The scan reveals an extensive aortic valve calcium score of 1,850 Agatston units, confirming anatomically severe calcification. The multidisciplinary Heart Team evaluates her elevated surgical risk and approves her for transcatheter aortic valve replacement via transfemoral access.

9. Measurement & Assessment

Accurate grading and quantification of aortic stenosis demand comprehensive multimodal cardiovascular imaging:

• Transthoracic Echocardiography (TTE): The gold-standard primary diagnostic instrument. Essential quantitative parameters include:
  • Peak Aortic Jet Velocity: Evaluated via continuous-wave Doppler ultrasound aligned parallel to transvalvular flow across multiple acoustic windows (apical, right parasternal, suprasternal).
  • Mean Transvalvular Gradient: Calculated by integrating the instantaneous gradients across the ejection interval using the modified Bernoulli formula (ΔP = 4v²).
  • Effective Valve Area (AVA): Derived using the continuity equation; indexed to body surface area (BSA) to correct for extremes of body habitus (≤0.6 cm²/m² indicating severe obstruction).
  • Dimensionless Velocity Index (DVI): The ratio of LVOT velocity-time integral to aortic valve velocity-time integral. A DVI <0.25 strongly signifies severe stenosis, independent of structural LVOT diameter measurement inaccuracies.
• Dobutamine Stress Echocardiography (DSE): Indicated in classical low-flow, low-gradient aortic stenosis (reduced ejection fraction) to assess contractile reserve (an increase in stroke volume ≥20% during graded dobutamine infusion) and differentiate true severe stenosis (valve area remains ≤1.0 cm² as gradient rises >40 mmHg) from pseudo-severe stenosis (valve area increases >1.0 cm² as stroke volume normalizes).
• Multidetector Computed Tomography (MDCT): Provides quantitative evaluation of aortic valve calcium scoring using the Agatston scale, free from hemodynamic loading conditions. Established sex-specific thresholds indicative of severe stenosis are ≥1,200–1,300 Agatston units in females and ≥2,000 Agatston units in males.
• Invasive Hemodynamic Catheterization: Reserved for cases with discordant non-invasive imaging or equivocal findings. Involves simultaneous recording of left ventricular pressure and ascending aortic pressure via double-lumen catheterization, applying the classic Gorlin equation.

10. Applications & Practical Significance

The clinical and public health significance of aortic stenosis is immense, driven by an aging global population and the high personal and economic costs of advanced valvular failure. Recognizing the timing of the transition from asymptomatic latency to symptomatic illness is critical. In asymptomatic individuals, annual mortality is low (<1%), but upon the onset of angina, syncope, or heart failure symptoms, average survival drops precipitously to 2 to 3 years unless mechanical relief of the obstruction is provided.

Management strategies rely on coordinated multidisciplinary care organized around institutional “Heart Teams,” comprising general cardiologists, imaging specialists, interventional cardiologists, and cardiac surgeons. Pharmacotherapy plays an exceptionally limited role; no pharmacological agent has been shown to halt or reverse leaflet calcification or mechanical stenosis. Statins, despite effectively reducing atherosclerotic cardiovascular events, consistently failed in clinical trials to slow aortic valve calcific progression. Medical management is thus restricted to careful treatment of concurrent hypertension, cautious administration of diuretics to treat pulmonary congestion, and the maintenance of sinus rhythm to preserve left atrial contribution to ventricular filling.

Definitive therapeutic management rests on intervention: either surgical aortic valve replacement (SAVR) via open sternotomy or minimally invasive thoracotomy, or aortic valve intervention via transcatheter approaches (TAVR). TAVR has expanded from high-risk and inoperable surgical candidates to intermediate- and low-risk demographics, driven by advancements in balloon-expandable and self-expanding delivery platforms, pre-procedural MDCT planning, cerebral embolic protection systems, and reduced vascular complication rates.

11. Research & Empirical Evidence

Modern clinical management of aortic stenosis is informed by landmark randomized controlled trials and large prospective registries. The pivotal PARTNER (Placement of Aortic Transcatheter Valves) and CoreValve trial programs established the therapeutic efficacy of transcatheter therapies:

PARTNER 1 demonstrated significant absolute reductions in mortality for inoperable and high-risk surgical patients undergoing TAVR compared with standard medical therapy and surgical intervention, respectively. Subsequent investigations, notably PARTNER 2, SURTAVI, PARTNER 3, and the Evolut Low Risk trial, extended these outcomes to intermediate- and low-surgical-risk cohorts, establishing non-inferiority and, in select parameters, superior 1- and 2-year composite endpoints of death, stroke, and rehospitalization for TAVR relative to conventional open surgery.

Concurrently, observational cohorts and clinical trials, including the CURRENT AS and RECOVERY trials, have challenged traditional conservative management in asymptomatic patients with very severe aortic stenosis (defined by peak transvalvular velocity ≥4.5–5.0 m/s). Findings from the RECOVERY trial demonstrated that early surgical intervention substantially reduced operative mortality and long-term cardiovascular death compared to a strategy of watchful waiting, prompting updates to international clinical practice guidelines.

In basic science, research continues to investigate biological targets capable of arresting calcific disease. Groundbreaking investigations using Mendelian randomization have identified elevated plasma levels of lipoprotein(a) as an independent causal driver of calcific aortic stenosis. Multiple clinical trials are currently investigating novel antisense oligonucleotides and small interfering RNA (siRNA) therapies designed to lower Lp(a) levels and assess their potential to slow disease progression.

12. Cultural & Cross-Cultural Considerations

The global epidemiological profile of aortic stenosis exhibits profound cross-cultural and regional variation, shaped primarily by national economic development, access to preventative healthcare, and population demographics. In high-income countries, calcific aortic stenosis of aging represents the overwhelming majority of cases, driven by prolonged life expectancy and modern demographic shifts toward older age groups.

Conversely, in numerous developing regions across Sub-Saharan Africa, South Asia, and parts of Latin America, rheumatic heart disease remains endemic. In these populations, aortic stenosis develops decades earlier, often affecting children, adolescents, and young adults, frequently coexisting with severe rheumatic mitral valve disease. Socioeconomic disparities, overcrowded living conditions, and restricted access to basic antibiotic therapies for streptococcal pharyngitis drive this persistence.

Disparities also characterize the availability of advanced therapeutics. While TAVR is widely utilized across high-income healthcare systems, its prohibitive cost, combined with the need for specialized hybrid operating suites and multidisciplinary teams, limits access in resource-constrained environments. In such settings, open surgical intervention using durable mechanical valves remains the primary treatment strategy, despite the lifelong requirement for systemic anticoagulation monitoring with warfarin.

13. Criticisms, Debates & Limitations

Despite significant diagnostic and therapeutic advances, several contentious debates persist in modern valvular cardiology:

• TAVR Durability in Younger Patients: As transcatheter approaches expand to lower-risk and younger populations (under age 65–70), questions persist regarding the long-term structural valve durability of transcatheter bioprostheses compared to established surgical valves. Structural valve deterioration, leaflet thrombosis, and accelerated calcification beyond 10 to 15 years remain active areas of study.
• Lifetime Management and Re-intervention: Transcatheter valve-in-valve (ViV) procedures offer a solution for failed bioprostheses, but repeat interventions introduce technical risks, including coronary artery obstruction, sinus sequestration, and patient-prosthesis mismatch due to residual gradients within constrained neo-annuli.
• Subclinical Leaflet Thrombosis: High-resolution four-dimensional computed tomography has identified hypo-attenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) in a subset of TAVR recipients. The clinical implications of these subclinical imaging findings regarding stroke risk, systemic embolization, and accelerated valve degradation remain actively debated.
• Conduction Abnormalities: TAVR procedures carry a higher incidence of new-onset high-grade atrioventricular block and bundle branch blocks compared to surgical valve replacement, stemming from mechanical compression of the cardiac conduction axis within the membranous septum, necessitating permanent pacemaker implantation in 8 to 20% of patients depending on the valve system used.

14. Related Terms & Distinctions

To prevent diagnostic errors, aortic stenosis must be differentiated from clinically and hemodynamically related cardiovascular conditions:

• Aortic Sclerosis: Characterized by focal or diffuse calcification and thickening of the aortic valve leaflets without significant functional outflow obstruction (peak velocity <2.0 m/s and mean gradient <10 mmHg). It represents a structural precursor to aortic stenosis and serves as an independent marker of atherosclerotic cardiovascular risk.
• Aortic Regurgitation: Characterized by the diastolic backflow of blood from the aorta into the left ventricle due to inadequate leaflet coaptation, imposing volume overload rather than pure pressure overload on the myocardium.
• Hypertrophic Obstructive Cardiomyopathy (HOCM): A primary genetic cardiomyopathy featuring dynamic left ventricular outflow tract obstruction caused by asymmetric septal hypertrophy and systolic anterior motion (SAM) of the anterior mitral leaflet, rather than fixed anatomical valvular narrowing.
• Subvalvular or Supravalvular Aortic Stenosis: Congenital anatomical obstructions located either proximal to the valve (e.g., discrete fibrous subaortic membranes) or distal to the valve (e.g., hourglass constriction of the ascending aorta, as observed in Williams syndrome).

15. Summary / Key Takeaways

Aortic stenosis is a complex, active biological disorder characterized by progressive fibrocalcific narrowing of the aortic valve orifice, leading to left ventricular pressure overload, compensatory hypertrophy, and eventual heart failure. While the condition remains asymptomatic during an extended latent period, the emergence of angina, syncope, or exertional dyspnea indicates severe mechanical compromise that carries high mortality without intervention. Contemporary diagnosis relies on multimodal imaging, primarily transthoracic echocardiography supported by computed tomography and stress testing for complex, low-gradient subtypes. Because medical therapy cannot reverse structural obstruction, definitive treatment depends on surgical or transcatheter valve replacement. The ongoing refinement of TAVR platforms, alongside evolving biological therapies targeting leaflet calcification pathways, continues to reshape the clinical management of this condition.

References

• Baumgartner, H., Hung, J., Bermejo, J., Chambers, J. B., Edvardsen, T., Goldstein, S., Lancellotti, P., LeFevre, M., Miller, F., & Otto, C. M. (2017). Recommendations on the echocardiographic assessment of aortic valve stenosis: A focused update from the European Association of Echocardiography and the American Society of Echocardiography. Journal of the American Society of Echocardiography, 30(4), 372–392. https://doi.org/10.1016/j.echo.2017.02.009
• Cribier, A., Eltchaninoff, H., Bash, A., Borenstein, N., Tron, C., Bauer, F., Derumeaux, G., Anselme, F., Laborde, F., & Leon, M. B. (2002). Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation, 106(24), 3006–3008. https://doi.org/10.1161/01.CIR.0000047200.36165.B8
• Mack, M. J., Leon, M. B., Thourani, V. H., Makkar, R., Kodali, S. K., Russo, M., Kapadia, S. R., Malaisrie, S. C., Cohen, D. J., Lu, M., Webb, J. G., & Smith, C. R. (2019). Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New England Journal of Medicine, 380(18), 1695–1705. https://doi.org/10.1056/NEJMoa1814052
• Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., O’Gara, P. T., Rigolin, V. H., Sundt, T. M., Thompson, A., & Toly, C. (2021). 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 143(5), e72–e227. https://doi.org/10.1161/CIR.0000000000000923
• Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., Gudnason, V., O’Donnell, C. J., & CHARGE Extracoronary Calcium Working Group. (2013). Genetic associations with valvular calcification and aortic stenosis. New England Journal of Medicine, 368(6), 503–512. https://doi.org/10.1056/NEJMoa1109034